Durable Response to Nivolumab in a Patient With Hepatic Sarcomatoid Carcinoma: Evolutive Characterization of Genomic and Immunohistochemical PD-L1 Expression Findings

JCO Precis Oncol. 2022 Aug:6:e2200163. doi: 10.1200/PO.22.00163.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen / genetics
  • Carcinoma*
  • Genomics
  • Humans
  • Lung Neoplasms* / metabolism
  • Nivolumab / therapeutic use

Substances

  • B7-H1 Antigen
  • Nivolumab